Recent Posts
Affordability, binding commitments to technology sharing, and transparency key in Pathogen Access and Benefit...
We appreciate the opportunity to offer comments on the draft PABS annex text .
Some preliminary comments:
Affordability of Access: The current draft mentions "providing access...
Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...
The IGWG process offers an opportunity to fulfil the equity objectives of the Pandemic...
Co-Chairs,
Thank you for the opportunity to make a brief intervention.
Both the sharing of pathogens and the sharing of the benefits, including products and knowledge,...
WHO Members meet to finalise the Pathogen Access and Benefit Sharing Instrument
In May 2025, the WHO member states adopted the Pandemic Agreement, but they left the work to establish an instrument for Pathogen Access and...
Treatment for cystic fibrosis added to Essential Medicines List by the World Health Organization:...
The World Health Organization today announced it has added the cystic fibrosis combination treatment elexacaftor + tezacaftor + ivacaftor (brand name Trikafta) to its...